Paul W Noble

List of Publications by Year
in descending order

86 papers	23,532 citations	31976 53 h-index	62596 80 g-index
94 all docs	94 docs citations	94 times ranked	18875 citing authors

#	Article	IF	Citations
1	Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. New England Journal of Medicine, 2014, 370, 2071-2082.	27.0	3,351
2	A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis. New England Journal of Medicine, 2014, 370, 2083-2092.	27.0	2,959
3	Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet, The, 2011, 377, 1760-1769.	13.7	1,711
4	Type 2 alveolar cells are stem cells in adult lung. Journal of Clinical Investigation, 2013, 123, 3025-3036.	8.2	1,352
5	Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nature Medicine, 2005, 11, 1173-1179.	30.7	1,291
6	Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis. New England Journal of Medicine, 2011, 365, 1079-1087.	27.0	930
7	Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, E1475-83.	7.1	849
8	Hyaluronan as an Immune Regulator in Human Diseases. Physiological Reviews, 2011, 91, 221-264.	28.8	848
9	Hyaluronan in Tissue Injury and Repair. Annual Review of Cell and Developmental Biology, 2007, 23, 435-461.	9.4	727
10	Resolution of Lung Inflammation by CD44. Science, 2002, 296, 155-158.	12.6	611
11	The Clinical Course of Patients with Idiopathic Pulmonary Fibrosis. Annals of Internal Medicine, 2005, 142, 963.	3.9	530
12	Hyaluronan and its catabolic products in tissue injury and repair. Matrix Biology, 2002, 21, 25-29.	3.6	491
13	Pulmonary fibrosis: patterns and perpetrators. Journal of Clinical Investigation, 2012, 122, 2756-2762.	8.2	429
14	Single-Cell Deconvolution of Fibroblast Heterogeneity in Mouse Pulmonary Fibrosis. Cell Reports, 2018, 22, 3625-3640.	6.4	392
15	Forced Vital Capacity in Patients with Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 1382-1389.	5.6	390
16	Six-Minute-Walk Test in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 1231-1237.	5.6	369
17	Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. European Respiratory Journal, 2016, 47, 243-253.	6.7	349
18	Idiopathic pulmonary fibrosis. Orphanet Journal of Rare Diseases, 2008, 3, 8.	2.7	332

#	Article	IF	Citations
19	Severe lung fibrosis requires an invasive fibroblast phenotype regulated by hyaluronan and CD44. Journal of Experimental Medicine, 2011, 208, 1459-1471.	8.5	322
20	Hyaluronan Fragments Induce Nitric-oxide Synthase in Murine Macrophages through a Nuclear Factor Î¹B-dependent Mechanism. Journal of Biological Chemistry, 1997, 272, 8013-8018.	3.4	264
21	Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. Lancet Respiratory Medicine,the, 2017, 5, 33-41.	10.7	240
22	Hyaluronan and TLR4 promote surfactant-protein-C-positive alveolar progenitor cell renewal and prevent severe pulmonary fibrosis in mice. Nature Medicine, 2016, 22, 1285-1293.	30.7	211
23	Alveolar Epithelial Type II Cells as Drivers of Lung Fibrosis in Idiopathic Pulmonary Fibrosis. International Journal of Molecular Sciences, 2020, 21, 2269.	4.1	202
24	Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial. Lancet Respiratory Medicine,the, 2017, 5, 22-32.	10.7	200
25	Flow Cytometric Analysis of Myeloid Cells in Human Blood, Bronchoalveolar Lavage, and Lung Tissues. American Journal of Respiratory Cell and Molecular Biology, 2016, 54, 13-24.	2.9	191
26	Interleukin-11 is a therapeutic target in idiopathic pulmonary fibrosis. Science Translational Medicine, 2019, 11, .	12.4	189
27	6-minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis. European Respiratory Journal, 2014, 43, 1421-1429.	6.7	180
28	Airway Epithelial Progenitors Are Region Specific and Show Differential Responses to Bleomycin-Induced Lung Injury. Stem Cells, 2012, 30, 1948-1960.	3.2	171
29	Hyaluronan as a therapeutic target in human diseases. Advanced Drug Delivery Reviews, 2016, 97, 186-203.	13.7	167
30	Hyaluronan Fragments Synergize with Interferon-Î³ to Induce the C-X-C Chemokines Mig and Interferon-inducible Protein-10 in Mouse Macrophages. Journal of Biological Chemistry, 1998, 273, 35088-35094.	3.4	161
31	Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis. Thorax, 2016, 71, 429-435.	5.6	151
32	Time for a change: is idiopathic pulmonary fibrosis still idiopathic and only fibrotic?. Lancet Respiratory Medicine,the, 2018, 6, 154-160.	10.7	137
33	Cellular Mechanisms of Tissue Fibrosis. 7. New insights into the cellular mechanisms of pulmonary fibrosis. American Journal of Physiology - Cell Physiology, 2014, 306, C987-C996.	4.6	133
34	Blocking follistatin-like 1 attenuates bleomycin-induced pulmonary fibrosis in mice. Journal of Experimental Medicine, 2015, 212, 235-252.	8.5	130
35	The role of Toll-like receptors in non-infectious lung injury. Cell Research, 2006, 16, 693-701.	12.0	129
36	Pre-existing traits associated with Covid-19 illness severity. PLoS ONE, 2020, 15, e0236240.	2.5	129

#	Article	IF	Citations
37	CD44 Is a Negative Regulator of Acute Pulmonary Inflammation and Lipopolysaccharide-TLR Signaling in Mouse Macrophages. Journal of Immunology, 2007, 178, 2469-2475.	0.8	127
38	CD44 Deficiency Leads to Enhanced Neutrophil Migration and Lung Injury in Escherichia coli Pneumonia in Mice. American Journal of Pathology, 2002, 161, 2219-2228.	3.8	119
39	An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP). Respiration, 2017, 94, 408-415.	2.6	116
40	Single-Cell Reconstruction of Human Basal Cell Diversity in Normal and Idiopathic Pulmonary Fibrosis Lungs. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1540-1550.	5.6	107
41	Transcription factor TBX4 regulates myofibroblast accumulation and lung fibrosis. Journal of Clinical Investigation, 2016, 126, 3063-3079.	8.2	101
42	Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials. BMJ Open Respiratory Research, 2016, 3, e000105.	3.0	96
43	Matrix Regulation of Lung Injury, Inflammation, and Repair: The Role of Innate Immunity. Proceedings of the American Thoracic Society, 2006, 3, 401-404.	3.5	93
44	Idiopathic pulmonary fibrosis: new insights into pathogenesis. Clinics in Chest Medicine, 2004, 25, 749-758.	2.1	92
45	Hyaluronan synthase 2â€“mediated hyaluronan production mediates Notch1 activation and liver fibrosis. Science Translational Medicine, 2019, 11, .	12.4	91
46	Role of hyaluronan and hyaluronan-binding proteins inÂhuman asthma. Journal of Allergy and Clinical Immunology, 2011, 128, 403-411.e3.	2.9	89
47	Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis. Respiratory Medicine, 2015, 109, 914-922.	2.9	85
48	Back to the Future. American Journal of Respiratory Cell and Molecular Biology, 2005, 33, 113-120.	2.9	83
49	Hyaluronan synthase 2 regulates fibroblast senescence in pulmonary fibrosis. Matrix Biology, 2016, 55, 35-48.	3.6	72
50	Lung Transplantation for Covid-19â€“Related Respiratory Failure in the United States. New England Journal of Medicine, 2022, 386, 1187-1188.	27.0	72
51	Targeting of TAM Receptors Ameliorates Fibrotic Mechanisms in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1443-1456.	5.6	66
52	PD-L1 on invasive fibroblasts drives fibrosis in a humanized model of idiopathic pulmonary fibrosis. JCI Insight, 2019, 4, .	5.0	64
53	Regulation of plasminogen activator inhibitor-1 and urokinase by hyaluronan fragments in mouse macrophages. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2000, 279, L707-L715.	2.9	63
54	Idiopathic Pulmonary Fibrosis: Natural History and Prognosis. Clinics in Chest Medicine, 2006, 27, 11-16.	2.1	56

#	Article	IF	Citations
55	Regulation of Nonâ€Infectious Lung Injury, Inflammation, and Repair by the Extracellular Matrix Glycosaminoglycan Hyaluronan. Anatomical Record, 2010, 293, 982-985.	1.4	54
56	Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment. Respiratory Medicine, 2019, 153, 44-51.	2.9	54
57	Syndecan-1 promotes lung fibrosis by regulating epithelial reprogramming through extracellular vesicles. JCI Insight, 2019, 4, .	5.0	50
58	MicroRNA-29c Prevents Pulmonary Fibrosis by Regulating Epithelial Cell Renewal and Apoptosis. American Journal of Respiratory Cell and Molecular Biology, 2017, 57, 721-732.	2.9	46
59	Categorization of lung mesenchymal cells in development and fibrosis. IScience, 2021, 24, 102551.	4.1	46
60	CD44 Deficiency Is Associated with Increased Bacterial Clearance but Enhanced Lung Inflammation During Gram-Negative Pneumonia. American Journal of Pathology, 2010, 177, 2483-2494.	3.8	43
61	Pirfenidone Initiates a New Era in the Treatment of Idiopathic Pulmonary Fibrosis. Annual Review of Medicine, 2016, 67, 487-495.	12.2	37
62	miR-323a-3p regulates lung fibrosis by targeting multiple profibrotic pathways. JCI Insight, 2016, 1, e90301.	5.0	37
63	The ZIP8/SIRT1 axis regulates alveolar progenitor cell renewal in aging and idiopathic pulmonary fibrosis. Journal of Clinical Investigation, 2022, 132, .	8.2	37
64	Methylation-mediated BMPER expression in fibroblast activation in vitro and lung fibrosis in mice in vivo. Scientific Reports, 2015, 5, 14910.	3.3	35
65	Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis. Chest, 2015, 148, 196-201.	0.8	35
66	Dose modification and dose intensity during treatment with pirfenidone: analysis of pooled data from three multinational phase III trials. BMJ Open Respiratory Research, 2018, 5, e000323.	3.0	35
67	Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis. Respiratory Research, 2019, 20, 55.	3.6	33
68	Idiopathic pulmonary fibrosis. New insights into classification and pathogenesis usher in a new era therapeutic approaches. American Journal of Respiratory Cell and Molecular Biology, 2003, 29, S27-31.	2.9	31
69	Risk factors for disease progression in idiopathic pulmonary fibrosis. Thorax, 2020, 75, 78-80.	5.6	22
70	Mitogen-activated Protein Kinaseâ€“activated Protein Kinase 2 Inhibition Attenuates Fibroblast Invasion and Severe Lung Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2019, 60, 41-48.	2.9	18
71	Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis. Advances in Therapy, 2019, 36, 2910-2926.	2.9	18
72	CC-90001, a c-Jun N-terminal kinase (JNK) inhibitor, in patients with pulmonary fibrosis: design of a phase 2, randomised, placebo-controlled trial. BMJ Open Respiratory Research, 2022, 9, e001060.	3.0	17

#	Article	IF	Citations
73	Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis: Impact of Timing of Treatment Initiation. Annals of the American Thoracic Society, 2019, 16, 927-930.	3.2	16
74	Mesenchymal growth hormone receptor deficiency leads to failure of alveolar progenitor cell function and severe pulmonary fibrosis. Science Advances, 2021, 7, .	10.3	10
75	Abnormal respiratory progenitors in fibrotic lung injury. Stem Cell Research and Therapy, 2022, 13, 64.	5.5	10
76	Antibody-mediated depletion of CCR10+ EphA3+ cells ameliorates fibrosis in IPF. JCI Insight, 2021, 6, .	5.0	9
77	Quantitative Image Analysis at Chronic Lung Allograft Dysfunction Onset Predicts Mortality. Transplantation, 2022, 106, 1253-1261.	1.0	6
78	Disruption of respiratory epithelial basement membrane in COVID-19 patients. Molecular Biomedicine, 2021, 2, 8.	4.4	4
79	Case Study Review. Chest, 2005, 128, 540S-546S.	0.8	3
80	The allograft injury marker CXCL9 determines prognosis of antiâ€HLA antibodies after lung transplantation. American Journal of Transplantation, 2021, , .	4.7	2
81	Stem Cells and Progenitor Cells in Interstitial Lung Disease. , 2022, , 158-168.		2
82	Take a deep breath: pulmonary research inspires. Journal of Clinical Investigation, 2012, 122, 2722-2723.	8.2	0
83	Pre-existing traits associated with Covid-19 illness severity. , 2020, 15, e0236240.		0
84	Pre-existing traits associated with Covid-19 illness severity. , 2020, 15, e0236240.		0
85	Pre-existing traits associated with Covid-19 illness severity. , 2020, 15, e0236240.		0
86	Pre-existing traits associated with Covid-19 illness severity. , 2020, 15, e0236240.		0